James R. Berenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James R. Berenson has a total of 521 co-authors. Here are the top co-authors by number of shared publications:
Haiming Chen
Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
38 shared publicationsTanya M. Spektor
Oncotherapeutics West Hollywood Los Angeles California USA
35 shared publicationsRegina A. Swift
Berenson Cancer Center West Hollywood Los Angeles California USA
25 shared publicationsMingjie Li
Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
23 shared publicationsSean Bujarski
Berenson Cancer Center, West Hollywood, CA, United States
22 shared publicationsRegina Swift
Berenson Cancer Center West Hollywood California USA
18 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Wiley in British Journal of Haematology
A real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study
Summary: Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently occur outside scheduled encounters and may remain unrecognized. A single‐centre pilot study evaluated the feasibility and clinical utility of a short message service (SMS)‐based remote monitoring platform, assessing 8 symptoms and 10 QoL domains for 58 MM patients over 90 days. End‐points included feasibility and engagement measured using completion rates, time burden and identification of clinically actionable events. A total of 1604 assessments were delivered, with an overall completion rate of 85.5%, and 72.4% of participants achieving >80% completion rate. Median completion time was 1.80 min. During the 90‐day study period, 215 predefined alerts were generated, of which 101 (47.0%) prompted clinical intervention within 48 h, frequently occurring outside routine clinic visits. SMS‐based remote monitoring demonstrated high feasibility, sustained engagement and minimal patient burden. This platform enabled real‐time identification of symptoms and facilitated rapid follow‐up by clinicians, supporting its potential for remote therapeutic monitoring rather than a passive data collection tool.
- 16 November 2026
- Published by Wiley in British Journal of Haematology
Open AccessA real‐time text‐based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study
Summary: Patient‐reported outcome (PRO) and quality of life (QoL) assessments for multiple myeloma (MM) patients are traditionally collected at infrequent intervals using burdensome instruments, resulting in limited clinical visibility between visits. This creates a critical gap in care, as evolving symptoms and treatment‐related toxicities frequently occur outside scheduled encounters and may remain unrecognized. A single‐centre pilot study evaluated the feasibility and clinical utility of a short message service (SMS)‐based remote monitoring platform, assessing 8 symptoms and 10 QoL domains for 58 MM patients over 90 days. End‐points included feasibility and engagement measured using completion rates, time burden and identification of clinically actionable events. A total of 1604 assessments were delivered, with an overall completion rate of 85.5%, and 72.4% of participants achieving >80% completion rate. Median completion time was 1.80 min. During the 90‐day study period, 215 predefined alerts were generated, of which 101 (47.0%) prompted clinical intervention within 48 h, frequently occurring outside routine clinic visits. SMS‐based remote monitoring demonstrated high feasibility, sustained engagement and minimal patient burden. This platform enabled real‐time identification of symptoms and facilitated rapid follow‐up by clinicians, supporting its potential for remote therapeutic monitoring rather than a passive data collection tool.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 410-416
Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
Introduction: Multiple myeloma (MM) is a bone marrow malignancy of plasma cells that can be treated with monoclonal antibodies (mAbs) including daratumumab. This mAb binds to CD38 proteins expressed on MM cells, allowing the immune system to recognize and kill these tumor cells. Neutropenia is a common complication in MM, often attributed to the disease itself or treatment with agents such as immunomodulatory drugs. However, its resolution with first-line mAb therapy has not previously been reported. Case Presentation: We report a case of a 32-year-old Filipino female with smoldering MM. She developed neutropenia and as a result was treated with a combination of daratumumab and glucocorticosteroids. She achieved a complete remission (CR), and her absolute neutrophil count normalized. The treatment was well tolerated with no adverse effects reported, and the patient remains in CR after more than 3 years of therapy. Discussion: This case highlights the potential for daratumumab combined with glucocorticosteroids alone to effectively manage a patient’s MM and severe neutropenia, suggesting a dual therapeutic benefit without treatment-related toxicity. Our findings support the consideration of daratumumab and glucocorticosteroids as a viable first-line therapeutic option for patients with MM who develop neutropenia.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 410-416
Open AccessTreatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report
Introduction: Multiple myeloma (MM) is a bone marrow malignancy of plasma cells that can be treated with monoclonal antibodies (mAbs) including daratumumab. This mAb binds to CD38 proteins expressed on MM cells, allowing the immune system to recognize and kill these tumor cells. Neutropenia is a common complication in MM, often attributed to the disease itself or treatment with agents such as immunomodulatory drugs. However, its resolution with first-line mAb therapy has not previously been reported. Case Presentation: We report a case of a 32-year-old Filipino female with smoldering MM. She developed neutropenia and as a result was treated with a combination of daratumumab and glucocorticosteroids. She achieved a complete remission (CR), and her absolute neutrophil count normalized. The treatment was well tolerated with no adverse effects reported, and the patient remains in CR after more than 3 years of therapy. Discussion: This case highlights the potential for daratumumab combined with glucocorticosteroids alone to effectively manage a patient’s MM and severe neutropenia, suggesting a dual therapeutic benefit without treatment-related toxicity. Our findings support the consideration of daratumumab and glucocorticosteroids as a viable first-line therapeutic option for patients with MM who develop neutropenia.
- Open Access
- 5 June 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (11) , 2823-2826
Outcomes for unselected, newly diagnosed multiple myeloma patients
- 5 June 2025
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (11) , 2823-2826
Open AccessOutcomes for unselected, newly diagnosed multiple myeloma patients
- 28 February 2025
- Published by Elsevier in Leukemia Research
- Vol. 151, 107677
Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study
- 28 February 2025
- Published by Elsevier in Leukemia Research
- Vol. 151, 107677
Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study
- 29 January 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (2) , 247-267
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with this disease. Key developments include the use of chemotherapy, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. MM remains incurable, with outcomes influenced by many factors, including age, sex, genetics, and treatment response. This review summarizes recent studies regarding monitoring and treatment of MM, emphasizing the efficacy of new therapies, the impact of maintenance treatments, and approaches for managing relapsed or refractory MM. The role of specific drug classes used to treat MM, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and newer treatments such as chimeric antigen receptor T-cell therapies and bispecific antibodies are discussed. Combination therapies have significantly improved outcomes. Maintenance therapies, particularly with lenalidomide, have been effective in extending OS but lead to an increased risk of secondary cancers. Venetoclax, selinexor, and ruxolitinib have shown potential as new therapeutic options for patients with relapsed or refractory MM. Immune-based treatments, such as chimeric antigen receptor T-cell therapy and bispecific antibodies, mark a major advancement for heavily pretreated patients, although challenges remain related to cost, availability, and side effects. The treatment landscape for patients with MM has seen significant progress, with current therapies providing a longer OS and better quality of life. Future research should focus on optimizing these strategies, personalizing therapies, and exploring new therapeutic targets.
- 29 January 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (2) , 247-267
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Multiple myeloma (MM) is a bone-marrow-based cancer of plasma cells. Over the last 2 decades, marked treatment advances have led to improvements in the overall survival (OS) of patients with this disease. Key developments include the use of chemotherapy, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. MM remains incurable, with outcomes influenced by many factors, including age, sex, genetics, and treatment response. This review summarizes recent studies regarding monitoring and treatment of MM, emphasizing the efficacy of new therapies, the impact of maintenance treatments, and approaches for managing relapsed or refractory MM. The role of specific drug classes used to treat MM, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and newer treatments such as chimeric antigen receptor T-cell therapies and bispecific antibodies are discussed. Combination therapies have significantly improved outcomes. Maintenance therapies, particularly with lenalidomide, have been effective in extending OS but lead to an increased risk of secondary cancers. Venetoclax, selinexor, and ruxolitinib have shown potential as new therapeutic options for patients with relapsed or refractory MM. Immune-based treatments, such as chimeric antigen receptor T-cell therapy and bispecific antibodies, mark a major advancement for heavily pretreated patients, although challenges remain related to cost, availability, and side effects. The treatment landscape for patients with MM has seen significant progress, with current therapies providing a longer OS and better quality of life. Future research should focus on optimizing these strategies, personalizing therapies, and exploring new therapeutic targets.
- 16 December 2024
- Published by Elsevier in Experimental Hematology
- Vol. 143, 104696
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation
- 16 December 2024
- Published by Elsevier in Experimental Hematology
- Vol. 143, 104696
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation
- Open Access
- 6 November 2024
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 16 (2) , 106-107
Medical writing bias in myeloma clinical research: A comprehensive analysis
- 6 November 2024
- Published by Wolters Kluwer Health in Perspectives in Clinical Research
- Vol. 16 (2) , 106-107
Open AccessMedical writing bias in myeloma clinical research: A comprehensive analysis
- Open Access
- 18 June 2024
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 17 (1) , 747-752
Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report
Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1–2% of patients, termed nonsecretory, do not produce these biomarkers. As the disease progresses, more patients may become unevaluable using conventional markers, requiring invasive and expensive procedures like BM biopsies and positron emission tomography-computed tomography (PET-CT) scans for assessment and highlighting the need for alternative methods to monitor disease progression. Case Presentation: We present a case report of an MM patient who developed nonsecretory disease during his second line of treatment when he complained of new rib pain; progressive disease was then confirmed on a PET-CT scan. The patient showed an increase in his serum B-cell maturation antigen (sBCMA) levels whereas his conventional myeloma markers did not detect disease activity (sMP remained undetectable and involved sFLC level was normal). After starting a new treatment regimen, his rib pain disappeared, PET-CT scan improved, and sBCMA levels decreased. Upon relapse, he developed increased rib pain with a rising sBCMA level; his conventional myeloma markers did not detect disease activity. After changing to a new regimen, his rib pain improved, and this was accompanied by a decrease in his sBCMA levels. Conclusion: Thus, this case exemplifies the potential for sBCMA to provide a non-invasive method for monitoring MM patients who develop nonsecretory disease.
- 18 June 2024
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 17 (1) , 747-752
Open AccessSerum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report
Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1–2% of patients, termed nonsecretory, do not produce these biomarkers. As the disease progresses, more patients may become unevaluable using conventional markers, requiring invasive and expensive procedures like BM biopsies and positron emission tomography-computed tomography (PET-CT) scans for assessment and highlighting the need for alternative methods to monitor disease progression. Case Presentation: We present a case report of an MM patient who developed nonsecretory disease during his second line of treatment when he complained of new rib pain; progressive disease was then confirmed on a PET-CT scan. The patient showed an increase in his serum B-cell maturation antigen (sBCMA) levels whereas his conventional myeloma markers did not detect disease activity (sMP remained undetectable and involved sFLC level was normal). After starting a new treatment regimen, his rib pain disappeared, PET-CT scan improved, and sBCMA levels decreased. Upon relapse, he developed increased rib pain with a rising sBCMA level; his conventional myeloma markers did not detect disease activity. After changing to a new regimen, his rib pain improved, and this was accompanied by a decrease in his sBCMA levels. Conclusion: Thus, this case exemplifies the potential for sBCMA to provide a non-invasive method for monitoring MM patients who develop nonsecretory disease.
- 20 April 2024
- Published by Springer Nature in Targeted Oncology
- Vol. 19 (3) , 343-357
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
Background Ruxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor, has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids both pre-clinically and clinically. Objective This study aims to evaluate whether LEN can achieve clinical activity among patients with multiple myeloma progressing on the combination of RUX and methylprednisolone (MP). Methods In this part of a phase I, multicenter, open-label study, we evaluated the safety and efficacy of RUX and MP for patients with multiple myeloma with progressive disease who had previously received a proteasome inhibitor, LEN, glucocorticosteroids, and at least three prior regimens; we also determined the safety and efficacy of adding LEN at the time of disease progression from the initial doublet treatment. Initially, all subjects received oral RUX 15 mg twice daily and oral MP 40 mg every other day. Those patients who developed progressive disease according to the International Myeloma Working Group criteria then received LEN 10 mg once daily on days 1–21 within a 28-day cycle in addition to RUX and MP, which were administered at the same doses these patients were receiving at the time progressive disease developed. Results Twenty-nine subjects (median age 64 years; 18 [62%] male) were enrolled in this part of the study and initially received the two-drug combination of RUX and MP. The median number of prior therapies was six (range 3–12). The overall response rate from this two-drug combination was 31% and the clinical benefit rate was 34%. The best responses were 1 very good partial response, 8 partial responses, 1 minor response, 12 stable disease, and 7 progressive disease. The median progression-free survival was 3.5 months (range 0.5–36.2 months). The median time to response was 3.0 months. The median duration of response was 12.5 months (range 2.8–36.2 months). Twenty (69%) patients who showed progressive disease had LEN added to RUX and MP; all patients had prior exposure to LEN and all but one patient was refractory to their last LEN-containing regimen. After the addition of LEN, the overall response rate was 30% and the clinical benefit rate was 40%. The best responses of patients following the addition of LEN were 2 very good partial responses, 4 partial responses, 2 minor responses, 8 stable disease, and 4 progressive disease. The median time to response was 2.6 months (range 0.7–15.0 months). The median duration of response was not reached. The median progression-free survival following the addition of LEN was 3.5 months (range 0.3–25.9 months). Conclusions For patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment. Clinical Trial Registration This study is registered with ClinicalTrials.gov, NCT03110822, and is ongoing.
- 20 April 2024
- Published by Springer Nature in Targeted Oncology
- Vol. 19 (3) , 343-357
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
Background Ruxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor, has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids both pre-clinically and clinically. Objective This study aims to evaluate whether LEN can achieve clinical activity among patients with multiple myeloma progressing on the combination of RUX and methylprednisolone (MP). Methods In this part of a phase I, multicenter, open-label study, we evaluated the safety and efficacy of RUX and MP for patients with multiple myeloma with progressive disease who had previously received a proteasome inhibitor, LEN, glucocorticosteroids, and at least three prior regimens; we also determined the safety and efficacy of adding LEN at the time of disease progression from the initial doublet treatment. Initially, all subjects received oral RUX 15 mg twice daily and oral MP 40 mg every other day. Those patients who developed progressive disease according to the International Myeloma Working Group criteria then received LEN 10 mg once daily on days 1–21 within a 28-day cycle in addition to RUX and MP, which were administered at the same doses these patients were receiving at the time progressive disease developed. Results Twenty-nine subjects (median age 64 years; 18 [62%] male) were enrolled in this part of the study and initially received the two-drug combination of RUX and MP. The median number of prior therapies was six (range 3–12). The overall response rate from this two-drug combination was 31% and the clinical benefit rate was 34%. The best responses were 1 very good partial response, 8 partial responses, 1 minor response, 12 stable disease, and 7 progressive disease. The median progression-free survival was 3.5 months (range 0.5–36.2 months). The median time to response was 3.0 months. The median duration of response was 12.5 months (range 2.8–36.2 months). Twenty (69%) patients who showed progressive disease had LEN added to RUX and MP; all patients had prior exposure to LEN and all but one patient was refractory to their last LEN-containing regimen. After the addition of LEN, the overall response rate was 30% and the clinical benefit rate was 40%. The best responses of patients following the addition of LEN were 2 very good partial responses, 4 partial responses, 2 minor responses, 8 stable disease, and 4 progressive disease. The median time to response was 2.6 months (range 0.7–15.0 months). The median duration of response was not reached. The median progression-free survival following the addition of LEN was 3.5 months (range 0.3–25.9 months). Conclusions For patients with multiple myeloma, treatment with RUX and MP is effective and well tolerated, and LEN can be used to extend the benefit of this RUX-based treatment. Clinical Trial Registration This study is registered with ClinicalTrials.gov, NCT03110822, and is ongoing.
- Open Access
- 5 February 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 65-75
Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Https://doi.org/10.18632/oncotarget.28547 Ashley Del Dosso, Elizabeth Tadevosyan, James R. Berenson
- 5 February 2024
- Published by Impact Journals, LLC in Oncotarget
- Vol. 15 (1) , 65-75
Open AccessPreclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma
Https://doi.org/10.18632/oncotarget.28547 Ashley Del Dosso, Elizabeth Tadevosyan, James R. Berenson